CARMEN-GC01: Phase II, open-label, single-arm study of tusamitamab ravtansine in combination with ramucirumab in pretreated patients with gastric or gastroesophageal junction adenocarcinoma (GA/GEJA)

Esposito, F. M.Lee, J.Rha, S. Y.Penkov, K. D.Moisseev, A.Van den Eynde, M.Prenen, H.2024-08-042024-08-0420220923-75341569-8041https://hdl.handle.net/11616/102537Annual Meeting of the European-Society-for-Medical-Oncology (ESMO) -- SEP 09-13, 2022 -- ELECTR NETWORK[Abstract Not Available]eninfo:eu-repo/semantics/closedAccess[No Keywords]CARMEN-GC01: Phase II, open-label, single-arm study of tusamitamab ravtansine in combination with ramucirumab in pretreated patients with gastric or gastroesophageal junction adenocarcinoma (GA/GEJA)Conference Object337S1124S1124WOS:000866211601522Q1